UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 97

of 'Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma'

97
TI
Resectability and survival in retroperitoneal sarcomas.
AU
Karakousis CP, Velez AF, Gerstenbluth R, Driscoll DL
SO
Ann Surg Oncol. 1996;3(2):150.
 
BACKGROUND: Retroperitoneal sarcomas historically have presented difficulties in their management due to a high rate of unresectability, which affects the survival of these patients.
METHODS: We retrospectively reviewed the charts of 87 consecutive patients with retroperitoneal sarcomas treated in the period 1977-1994.
RESULTS: The resectability rate was 100% for the primary tumors (n = 55) and 87% for the locally recurrent tumors (n = 32). The 5-year survival rate was 63% (66% for the primary tumors and 57% for those with local recurrence). The 10-year survival rate was 46% (57% for primary tumors and 26% for those referred with locally recurrent tumor). The overall local recurrence rate was 31% (25% for the primary tumors and 41% for those referred with local recurrence); it was 56% after local excision and 15% after wide resection (p = 0.0003). The 10-year disease-free survival of patients with local excision (n = 25) was 7%, and that of patients with wide resection (n = 54) 59% (p = 0.0001).
CONCLUSIONS: The overall resectability rate of retroperitoneal sarcomas was 95%. Wideresection produced a significantly higher survival rate compared with that of local excision. The survival rate for the primary tumors, varying significantly with the histologic grade, approached the rate reported for primary soft-tissue sarcomas of the extremity.
AD
Millard Fillmore Hospitals, Buffalo 14209, USA.
PMID